Afinitor Shortage: What Providers and Prescribers Need to Know in 2026

Everolimus (Afinitor) remains a cornerstone therapy across multiple oncology indications, from HR+/HER2- breast cancer to neuroendocrine tumors and TSC-associated conditions. But patient access to this medication continues to be more complicated than the prescribing itself.

This briefing covers the current supply landscape, generic developments, prescribing implications, cost and access challenges, and tools to help your patients obtain their medication without treatment interruptions.

Current Supply Status

As of Q1 2026, Afinitor and generic Everolimus are not listed on the FDA Drug Shortage Database. Manufacturing supply appears stable across both the brand and generic markets.

However, clinicians should be aware that patient-reported difficulty obtaining Everolimus remains common. This is driven primarily by:

• Specialty pharmacy distribution requirements
• Prior authorization and step therapy mandates
• The high unit cost limiting pharmacy inventory ($18,413–$19,260 per 28-day supply for brand)
• Formulation-specific gaps, particularly for Afinitor Disperz

The supply issue is functionally one of access and distribution, not manufacturing capacity.

Timeline: Key Developments

• March 2009: Afinitor (Everolimus) first approved by FDA for advanced renal cell carcinoma
• 2010–2016: Additional indications approved — SEGA/TSC (2010), PNET (2011), HR+/HER2- breast cancer (2012), GI/lung NET (2016), TSC-related seizures (2018)
• 2020–2023: First generic Everolimus tablets approved, initially at limited strengths
• January 2025: Breckenridge Pharmaceutical receives FDA final approval for generic Everolimus Tablets for Oral Suspension (AB-rated to Afinitor Disperz) in 2 mg, 3 mg, and 5 mg — the first generic Disperz equivalent
• 2025–2026: Multiple generic manufacturers now produce Everolimus tablets across all four strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg)

Prescribing Implications

Generic Substitution

Generic Everolimus tablets are AB-rated to Afinitor and can be substituted at the pharmacy level in most states. Clinicians prescribing Afinitor should be aware that:

• Pharmacies may automatically dispense the generic unless "Dispense as Written" (DAW) is specified
• Generic and brand formulations are bioequivalent; no dose adjustment is needed when switching
• For patients on Afinitor Disperz, a generic equivalent is now available (Breckenridge, approved January 2025)
• Therapeutic drug monitoring (trough levels) remains appropriate for SEGA/TSC indications regardless of formulation

Prior Authorization Considerations

Nearly all payers require prior authorization for Everolimus products. Common documentation requirements include:

• Confirmed diagnosis within an FDA-approved indication
• Documentation that the prescriber is an oncologist, neurologist, nephrologist, or relevant specialist
• For breast cancer: failure of prior endocrine therapy (letrozole or anastrozole)
• For RCC: failure of prior VEGF-targeted therapy (sunitinib or sorafenib)
• For TSC-SEGA: documentation that the lesion is not amenable to curative resection

Approval durations vary by payer — typically 6–12 months for commercial plans. Proactive renewal submissions can prevent treatment gaps.

Drug Interactions of Clinical Significance

When prescribing Everolimus, be mindful of the following CYP3A4-mediated interactions:

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole): Significantly increase Everolimus exposure. Avoid concomitant use or reduce Everolimus dose.
• Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, phenobarbital): Significantly decrease Everolimus exposure. Consider doubling the Everolimus dose per labeling guidance.
• Moderate CYP3A4 inhibitors (erythromycin, fluconazole, verapamil, diltiazem): May require Everolimus dose reduction.
• ACE inhibitors: Increased risk of angioedema with concurrent use.

Counsel patients to avoid grapefruit, grapefruit juice, and St. John's wort. For a comprehensive reference, see Afinitor Drug Interactions: What to Avoid.

Availability and Distribution

Everolimus is distributed primarily through specialty pharmacies. Most major payers and PBMs contract with specific specialty pharmacy networks for oncology medications. Key considerations for your practice:

• Identify your patients' designated specialty pharmacy before writing the prescription to avoid delays
• Specialty pharmacies typically ship directly to patients — confirm the patient's shipping address and availability to receive temperature-sensitive packages
• Inventory varies by strength — if a specific strength is unavailable, consult with the pharmacy about using a combination of available strengths to achieve the prescribed dose
• Afinitor Disperz may have more limited availability than standard tablets, even with the new generic option

Cost and Access Landscape

The cost differential between brand and generic Everolimus is dramatic:

• Brand Afinitor: $18,413–$19,260/month
• Generic Everolimus (with discount card): As low as $90/month
• Generic Everolimus (cash): ~$4,030/month
• Afinitor Disperz (brand): ~$11,587/month

For commercially insured patients with high copays, the Novartis Oncology Universal Co-pay Program provides up to $15,000 per year in copay assistance. For uninsured or underinsured patients, the Novartis Patient Assistance Foundation (NPAF) at pap.novartis.com provides the drug at no cost.

Your practice's financial counselor or social worker can also help patients navigate manufacturer assistance programs, foundation grants, and state pharmaceutical assistance programs.

Tools and Resources for Your Practice

• Medfinder for Providers — Real-time pharmacy stock checking tool. Help your patients locate Everolimus at pharmacies near them without the phone tag.
• Novartis Patient Support: 1-800-277-2254 or pap.novartis.com
• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages — Check for official shortage notices
• ASHP Drug Shortage Resource Center: ashp.org/drug-shortages — Additional shortage tracking and clinical recommendations

For additional provider-focused guidance on helping patients find Afinitor, see How to Help Your Patients Find Afinitor in Stock: A Provider's Guide.

Looking Ahead

The Everolimus market is becoming increasingly genericized, which is positive for patient access and affordability. Key trends to watch in 2026:

• Additional generic manufacturers entering the market should further reduce prices and improve stock
• Biosimilar and next-generation mTOR inhibitor development continues, though no new approvals are imminent
• Payer policies may shift toward requiring generic Everolimus over brand-name Afinitor as generic competition increases
• Specialty pharmacy consolidation continues to impact how oncology drugs are distributed

Final Thoughts

Afinitor's supply challenges in 2026 are primarily access-related, not manufacturing-related. As prescribers, the most impactful steps you can take are: prescribing generic Everolimus when appropriate, proactively managing prior authorization, connecting patients with financial assistance, and using tools like Medfinder to help patients locate available inventory.

Treatment interruptions in oncology carry real clinical consequences. A few minutes of coordination upfront can prevent weeks of delay for your patients.